Startseite

Aktien

Akero Therapeutics

Nachrichten

Akero Therapeutics Aktie

Aktie

ISIN: US00973Y1082 WKN: A2PLNP SYM: 0K4 Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

46,84

EUR

-0,15 %

-0,07 EUR

Letzter Kurs 05.12.25 Tradegate

Akero Therapeutics Aktie kaufen

Geldkurs

05.12.25

46,46

EUR

129 STK

Briefkurs

05.12.25

47,21

EUR

127 STK

Verkauf

Kauf

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Neueste Nachrichten

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO 20.11.25 · Business Wire (engl.) · Akero Therapeutics
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting 2025 07.11.25 · globenewswire · Akero Therapeutics
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO 11.10.25 · Business Wire (engl.) · Akero Therapeutics
AKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to Shareholders 09.10.25 · Business Wire (engl.) · Akero Therapeutics
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion 09.10.25 · globenewswire · Akero Therapeutics
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting 2025 07.10.25 · globenewswire · Akero Therapeutics
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference 28.08.25 · globenewswire · Akero Therapeutics
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH 15.08.25 · globenewswire · Akero Therapeutics
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update 08.08.25 · globenewswire · Akero Therapeutics
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 03.06.25 · globenewswire · Akero Therapeutics
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference 28.05.25 · globenewswire · Akero Therapeutics
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update 12.05.25 · globenewswire · Akero Therapeutics

1
2
…
3

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin ... 132 Leser
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero ... 120 Leser

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study ... 688 Leser
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded ... 228 Leser
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded ... 200 Leser
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal ... 192 Leser
Akero Therapeutics Announces Proposed Public Offering of Common Stock 168 Leser
Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im New England Journal of ... 168 Leser
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial ... 164 Leser
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... 164 Leser
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der ... 160 Leser
Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase-IIb-Studie HARMONY in ... 144 Leser